ClinicalTrials.gg
Enrolling by invitationNCT05872191Updated Oct 15, 2026

Psychometric Study of the Spanish Version of Two Upper Limb Assessment Scales in Chronic Stroke

An observational study in Chronic Stroke, sponsored by University of Valencia. Enrolling by invitation at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by University of Valencia · Observational

How we know

Updated Oct 15, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Stroke by University of Valencia — 3 open to participants now, 3 under way, none of them phase 3. Stroke · University of Valencia.

Started
2023
the only one that year
Observational
3 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Stroke by University of Valencia, this one is the only one that started in 2023, is one of 3 observational ones, and was the 10th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

3 of the 11 studies in Stroke by University of Valencia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Stroke by University of Valencia, or all of them as a file.
02

Study summary

The purpose of this cross-sectional study is to translate and cross-culturally adapt to Spanish the Motor Evaluation Scale for Upper Extremity in Stroke Patients (MESUPES) and the Stroke Upper Limb Capacity Scale (SULCS) and to assess their psychometric properties in Spanish people with chronic stroke.

Read the detailed description

Stroke is the second cause of mortality and the first cause of acquired disability in Spain. In the coming years, due to the progressive ageing of the European population, the incidence of this disease is expected to increase. Current epidemiological studies estimate that one out of six people are likely to suffer a stroke during their lifetime in Spain.

The sequelae from stroke are very varied, with hemiparesis being one of the most commonly observed. The involvement of the upper limb is frequent in people with this sequela in the acute phase, affecting to 70% of them approximately, with the limitations that this can cause. It is therefore necessary to have instruments that quantify these functional changes and that must be sensitive, reliable and valid tools. These would allow treatment goals to be set, interventions to be planned and results to be recorded to determine effectiveness in an appropriate way.

Several scales are currently available to assess functional impairment of the upper extremity (UE) after stroke. For example, the Stroke Upper Limb Capacity Scale (SULCS) was developed with the idea of being a simple to use and unidimensional instrument to assess this population. It was the first scale that included simple functions items (minimal hand use) and highly demands manipulative items. Similarly, the Motor Evaluation Scale for Upper Extremity in Stroke Patients (MESUPES) quickly assesses quantity and quality of movement in the UE after stroke, and can be used to assess people with no muscle activation and still be sensitive to assess people with minimal motor impairment.

On the other hand, the linguistic and cultural adaptation of health assessment instruments is becoming necessary, given the increase of multinational research. Moreover, in countries with a multicultural population, this factor needs to be taken into account as it can have a direct effect on the measures recorded. The quality of healthcare is highly dependent on an accurate assessment process, which in turn will depend on an understanding of the cultural, linguistic and ethical context of each individual. Due to the increasingly diversified world population caused by globalisation, this need is increasing. The process of translating, adapting and validating a scale requires very rigorous planning and methodology so that a reliable and valid measure can be obtained for the target population.

The aim of this study is two-fold: first, to translate and cross-culturally adapt to Spanish the "Motor Evaluation Scale for Upper Extremity in Stroke Patients (MESUPES)" and the "Stroke Upper Limb Capacity Scale (SULCS)"; and second to assess the psychometric properties of the Spanish versions of both scales in Spanish people with chronic stroke.

To cope with the study objectives, first, the translation and cross-culturally adaptation to Spanish of both scales was performed following the international recommendations. Next, a cross-sectional and psychometric study will be carried out. Participants will be assessed in two day visits (baseline and re-test), with no less than one week and no more than two weeks between them. In both visits, the two target scales will be performed. Additionally, in the first appointment, clinical, demographic and anthropometric data and cognitive function will be collected, and questionnaires and clinical tests will be carried out to study the reliability and validity of the target scales.

03

Conditions studied

  • Chronic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Spanish-native speakers with functional impairment of the upper extremity after stroke in chronic phase.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Spanish-native speakers aged between 18 and 80 years with:

  • Functional impairment of the upper extremity due to hemiparesis secondary to a stroke of ≥6 months of evolution
  • Clinical stability
  • Sufficient cognitive capacity to give consent to participate in the study and to understand and perform the assessment tests

Exclusion criteria

Exclusion Criteria:

  • Bilateral motor impairment
  • Neurological impairment other than stroke (both central and peripheral nervous systems), musculoskeletal impairment (amputation, fracture, etc.) or disabling pain (Visual Analogue Scale score > 5) that may affect the performance of the tests
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Upper extremity functional impairment due to chronic stroke

    Spanish-native speakers with functional impairment of the upper extremity after stroke in chronic phase.

    Other: No intervention

Interventions

  • OtherNo intervention

    There is no intervention to be administered, only collection of data through various tests and questionnaires.

06

What researchers measure

Primary outcomes

  1. Change of functional impairment of the hemiparetic upper extremity: Motor Evaluation Scale for Upper Extremity in Stroke Patients (MESUPES).

    The MESUPES assesses the quality of movement performance of the hemiparetic arm and hand in people with stroke. It is a 17-item scale divided into two subscales: one for arm function (8 items with 6 response categories (0-5)) and other for hand function ("range of motion" 6 items; and "orientation during functional tasks" 3 items, with 3 response categories (0-2)). The maximum achievable score is 58 (MESUPES-Arm maximum score is 40; MESUPES-Hand maximum score is 18), with higher scores indicating better function

    Time frame: Change from baseline to re-test

  2. Change of functional impairment of the hemiparetic upper extremity: Stroke Upper Limb Capacity Scale (SULCS)

    The SULCS is a 10-item scale in which the ability to perform daily activities with the hemiparetic upper limb in increasing difficulty is assessed. The scoring is dichotomous (0, unable to perform the task; 1, able to perform the task). This results in a sum score ranging from 0 to 10 with higher scores indicating better functional capacity.

    Time frame: Change from baseline to re-test

Secondary outcomes

  1. Cognitive function: Montreal Cognitive Assessment (MoCA)

    The MoCA is a screening instrument for detecting cognitive impairment that assesses multiple cognitive domains (attention, concentration, executive functions, memory, language, visuospatial skills, abstraction, calculation and orientation). The total score ranges from 0 to 30 points, with a score ≥ 26 considered to be normal.

    Time frame: The cohort group will be assessed at baseline

  2. Disability: Modified Rankin Scale (mRS)

    The mRS is a single-item measure of functional independence in which patients are asked about their overall health, their ease in carrying out ADLs (cooking, eating, dressing) and other factors about their life. The mRS result is reported on a 6-point scale (grade 0, indicating a lack of symptoms, and grade 5 indicating severe disability).

    Time frame: The cohort group will be assessed at baseline

  3. Stroke impact: Stroke Impact Scale v 3.0. (SIS)

    The SIS is a stroke-specific, self-report, health status measure. The SIS version 3.0 includes 59 items and assesses 8 domains: strength (four items), memory and thinking (seven items), emotion (nine items), communication (seven items), participation/role function (eight items), mobility (9 items), hand function (five items) and basic/instrumental activities of daily living (10 items). Each item is rated using a 5-point Likert-type scale (1 = an inability to complete the item; 5 = no difficulty experienced at all) and a global scores is calculated as a summative score of each domain, transformed into a 0-100 scale. It includes an extra question on the person´s perceived stroke recovery measured in the form of a visual analogue scale from 0-100.

    Time frame: The cohort group will be assessed at baseline

  4. Muscle spasticity: Modified Ashworth Scale (MAS)

    The MAS is a muscle tone assessment scale used to assess the resistance experienced during passive range of motion. Each movement is rated on a 6-point scale, with higher scores indicating higher spasticity. The muscle tone of the shoulder, elbow and wrist will be assessed.

    Time frame: The cohort group will be assessed at baseline

  5. Motor function: Fugl-Meyer Assessment- Upper Limb (FMA-UE)

    The upper extremity motor domain of the Fugl-Meyer-Assessment will be used. It includes 33 items assessing movement, coordination, and reflex action of the shoulder, elbow, forearm, wrist and hand. Scoring is based on direct observation of performance, with each item scored on a 3-level ordinal scale (0 = unable to perform, 2 = near normal ability). The maximal achievable score is 66, being higher scores indicative of better motor function.

    Time frame: The cohort group will be assessed at baseline

  6. Upper limb strength: Motricity Index (MI)

    The MI is used to assess motor impairment after stroke. The upper extremity tests include shoulder abduction, elbow flexion and pinch grip. These three actions are scored each on a 33- point scale according to the MI instructions. A total upper extremity score is obtained by adding one to the sum of the three actions scores, with a maximum possible result of 100. Higher scores are indicative of less motor impairment.

    Time frame: The cohort group will be assessed at baseline

  7. Manual dexterity: Box and Blocks Test (BBT)

    The BBT is a performance based test of gross manual dexterity. It consists of moving as many wooden blocks as possible, one at a time, from one compartment of a partitioned box to the other, within 60 seconds. The test is scored by counting the number of blocks transferred (the higher the number of blocks transferred, the better the outcome).

    Time frame: The cohort group will be assessed one week after baseline

  8. Digital dexterity: 9-Hole Peg Test (9HPT)

    The 9HPT is a single-task performance based measure of digital dexterity. The test involves placing and removing nine pegs on a pegboard as quickly as possible, while timed. The quicker the pins are inserted and taken out, the better the outcome.

    Time frame: The cohort group will be assessed one week after baseline

  9. Motor function: Action Research Arm Test (ARAT)

    The ARAT is a 19-item test designed to assess upper extremity function and dexterity (grasp, grip, pinch and gross movement). Each item is scored on a 4-point ordinal scale (0 =no movement; 3= normal performance of the task), while the total score ranges from 0 to 57, with higher scores indicating better performance.

    Time frame: The cohort group will be assessed one week after baseline

  10. Activities of daily living: Bimanual Hand Ability (ABILHAND)

    The ABILHAND assesses the person's perceived difficulty in using the hand to perform manual activities in daily activities unaided. It is a 23-item self-report questionnaire than includes common bimanual activities (e.g. hammering a nail, wrapping gifts, cutting meat, buttoning a shirt, opening mail). Each task is scored on a 3-point scale (0=impossible, 1=difficult, 2=easy). Analysis of the answers is via a Rasch model of online analysis, which converts the raw scores into a linear measure (in logits). The higher the positive logits are, the better the person's ability.

    Time frame: The cohort group will be assessed one week after baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2027, 48 months after the start.

Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 48 months is above that.

Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jan 2026 → Dec 2027 and completion Jun 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2023
First posted
May 24, 2023
StartActual
Dec 1, 2023
Primary completionEst.
Dec 31, 2027was Jan 2026
CompletionEst.
Dec 31, 2027was Jun 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • University of Valencia · Valencia, Spain
Show 1 removed
  • University of Valencia · Valencia, Spain
Oct 15, 2026
Primary completion
Jan 2026→Dec 31, 2027
Oct 15, 2026
Study completion
Jun 2026→Dec 31, 2027
Oct 15, 2026
Eligibility
Revised
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    1 site added, 1 site removed
    Show site
    • University of Valencia · Valencia, Spain
    Show 1 removed
    • University of Valencia · Valencia, Spain
    Primary completion Jan 2026→Dec 31, 2027
    Study completion Jun 2026→Dec 31, 2027
    Eligibility Revised
    + 4 other changes: identifiers, verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05872191
Responsible party
M Luz Sanchez (Associate Professor of Physiotherapy, University of Valencia) — Principal investigator
First posted
May 24, 2023
Start date
Dec 1, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Maria-Arantzazu Ruescas-Nicolau, PT, PhD
principal investigator · Department of Physiotherapy, University of Valencia (Spain)
M.Luz Sánchez-Sánchez, PT, PhD
principal investigator · Department of Physiotherapy, University of Valencia (Spain)
Lirios Dueñas, PT, PhD
study director · Department of Physiotherapy, University of Valencia (Spain)
Monja Spotti, PT, MSc
study chair · Faculty of Physiotherapy, University of Valencia (Spain)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion